Hong Kong Journal of Nephrology
Volume 8, Issue 1 , Pages 10-16, April 2006

Cardiovascular Disease in End-stage Renal Disease

  • Angela Yee-Moon Wang

      Affiliations

    • Corresponding Author InformationAddress correspondence and reprint requests to: Dr Wang Angela Yee-Moon, University Department of Medicine, Queen Mary Hospital, University of Hong Kong, 102 Pokfulam Road, Hong Kong SAR, China. Fax: (+852) 2855-5411
    • ,
  • Daniel Tak-Mao Chan
    • ,
  • Kar-Neng Lai

University Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pokfulam, Hong Kong SAR, China

Article Outline

Cardiovascular disease is the leading cause of morbidity and mortality in patients with end-stage renal disease. It accounts for nearly half of the mortality in end-stage renal disease patients on maintenance dialysis treatment. The spectrum of cardiovascular disease is diverse, including vascular disease and myocardial disease, and the two commonly coexist and are interrelated with each other. Apart from considering the traditional Framingham risk factors, there is increasing recognition of the importance of non-traditional risk factors in predisposing patients with end-stage renal disease to this high incidence of cardiovascular complications, including excessive calcium phosphorus load, hyperparathyroidism, anemia, hemodynamic overload, inflammation, increased asymmetric dimethylarginine and oxidative stress. Cardiovascular disease in end-stage renal disease patients commonly manifests as ischemic heart disease or acute coronary syndrome, stroke, peripheral vascular disease and congestive heart failure. According to the United States Renal Data System, the annual incidence of new-onset ischemic heart disease, stroke, peripheral vascular disease and congestive heart failure was estimated to be approximately 5%, 1%, 7% and 7%, respectively. In order to improve the cardiovascular outcomes of end-stage renal disease patients receiving maintenance dialysis therapy, a better understanding of the nature and severity of cardiovascular disease as well as risk factors associated with the different cardiovascular complications is required.

Key words:  atherosclerosis , calcification , cardiovascular , dialysis , end-stage kidney disease , heart failure , ventricular hypertrophy

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Levey AS , Beto JA , Coronado BE , Eknoyan G , Foley RN , Kasiske BL , et al.   Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease . Am J Kidney Dis . 1998;32:853–906
  2. Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients . J Am Soc Nephrol . 2004;15:2186–2194
  3. Wang AY , Woo J , Lam CW , Wang M , Sea MM , Lui SF , et al.   Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? . J Am Soc Nephrol . 2003;14:1871–1879
  4. Anavekar NS , McMurray JJ , Velazquez EJ , Solomon SD , Kober L , Rouleau JL , et al.   Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction . N Engl J Med . 2004;351:1285–1295
  5. Mann JF , Gerstein HC , Pogue J , Bosch J , Yusuf S . Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial . Ann Intern Med . 2001;134:629–636
  6. Muntner P , He J , Hamm L , Loria C , Whelton PK . Renal insuffi-ciency and subsequent death resulting from cardiovascular disease in the United States . J Am Soc Nephrol . 2002;13:745–753
  7. Weiner DE , Tighiouart H , Amin MG , Stark PC , MacLeod B , Griffith JL , et al.   Chronic kidney disease as a risk factor for cardio-vascular disease and all-cause mortality: a pooled analysis of community-based studies . J Am Soc Nephrol . 2004;15:1307–1315
  8. Go AS , Chertow GM , Fan D , McCulloch CE , Hsu CY . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization . N Engl J Med . 2004;351:1296–1305
  9. Ketteler M , Gross ML , Ritz E . Calcification and cardiovascular problems in renal failure . Kidney Int Suppl . 2005;94:S120–S127
  10. Blacher J , Guerin AP , Pannier B , Marchais SJ , London GM . Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease . Hypertension . 2001;38:938–942
  11. London GM , Guerin AP , Marchais SJ , Metivier F , Pannier B , Adda H . Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality . Nephrol Dial Transplant . 2003;18:1731–1740
  12. He ZX, Hedrick TD, Pratt CM, Verani MS, Aquino V, Roberts R, et al. Severity of coronary artery calcification by electron beam computed tomography predicts silent myocardial ischemia . Circulation . 2000;101:244–251
  13. Haydar AA , Hujairi NM , Covic AA , Pereira D , Rubens M , Goldsmith DJ . Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography . Nephrol Dial Transplant . 2004;19:2307–2312
  14. Haydar AA , Covic A , Colhoun H , Rubens M , Goldsmith DJ . Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients . Kidney Int . 2004;65:1790–1794
  15. Blacher J , Guerin AP , Pannier B , Marchais SJ , Safar ME , London GM . Impact of aortic stiffness on survival in end-stage renal disease . Circulation . 1999;99:2434–2439
  16. London GM , Parfrey PS . Cardiac disease in chronic uremia: pathogenesis . Adv Ren Replace Ther . 1997;4:194–211
  17. London GM , Marchais SJ , Guerin AP , Metivier F , Adda H . Arterial structure and function in end-stage renal disease . Nephrol Dial Transplant . 2002;17:1713–1724
  18. Wang AY , Ho SS , Wang M , Liu EK , Ho S , Li PK , et al.   Cardiac valvular calcification as a marker of atherosclerosis and arterial calcification in end-stage renal disease . Arch Intern Med . 2005;165:327–332
  19. Varma R, Aronow WS, McClung JA, Garrick R, Vistainer PF, Weiss MB, et al. Prevalence of valve calcium and association of valve calcium with coronary artery disease, atherosclerotic vascular disease, and all-cause mortality in 137 patients undergoing hemodialysis for chronic renal failure . Am J Cardiol . 2005;95:742–743
  20. Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study . J Am Soc Nephrol . 2003;14:159–168
  21. Braun J , Oldendorf M , Moshage W , Heidler R , Zeitler E , Luft FC . Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients . Am J Kidney Dis . 1996;27:394–401
  22. Goodman WG , Goldin J , Kuizon BD , Yoon C , Gales B , Sider D , et al.   Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis . N Engl J Med . 2000;342:1478–1483
  23. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? . J Am Coll Cardiol . 2002;39:695–701
  24. Chertow GM , Burke SK , Raggi P  Treat to Goal Working Group . Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients . Kidney Int . 2002;62:245–252
  25. Chertow GM , Raggi P , Chasan-Taber S , Bommer J , Holzer H , Burke SK . Determinants of progressive vascular calcification in haemodialysis patients . Nephrol Dial Transplant . 2004;19:1489–1496
  26. Wang AY , Woo J , Wang M , Sea MM , Ip R , Li PK , et al.   Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients . J Am Soc Nephrol . 2001;12:1927–1936
  27. Oh J , Wunsch R , Turzer M , Bahner M , Raggi P , Querfeld U , et al.   Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure . Circulation . 2002;106:100–105
  28. Ketteler M , Bongartz P , Westenfeld R , Wildberger JE , Mahnken AH , Bohm R , et al.   Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study . Lancet . 2003;361:827–833
  29. Stenvinkel P , Wang K , Qureshi AR , Axelsson J , Pecoits-Filho R , Gao P , et al.   Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin . Kidney Int . 2005;67:2383–2392
  30. Wang AY , Woo J , Lam CW , Wang M , Chan IH , Gao P , et al.   Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients . Nephrol Dial Transplant . 2005;20:1676–1685
  31. Parfrey PS , Foley RN , Harnett JD , Kent GM , Murray D , Barre PE . Outcome and risk factors of ischemic heart disease in chronic uremia . Kidney Int . 1996;49:1428–1434
  32. Herzog CA , Ma JZ , Collins AJ . Poor long-term survival after acute myocardial infarction among patients on long-term dialysis . N Engl J Med . 1998;339:799–805
  33. Rostand SG , Kirk KA , Rutsky EA . Dialysis-associated ischemic heart disease: insights from coronary angiography . Kidney Int . 1984;25:653–659
  34. Hansson GK . Inflammation, atherosclerosis, and coronary artery disease . N Engl J Med . 2005;352:1685–1695
  35. Ross R . Atherosclerosis – an inflammatory disease . N Engl J Med . 1999;340:115–126
  36. Yao Q , Axelsson J , Stenvinkel P , Lindholm B . Chronic systemic inflammation in dialysis patients: an update on causes and consequences . ASAIO J . 2004;50:lii–lvii
  37. Ducloux D , Bresson-Vautrin C , Kribs M , Abdelfatah A , Chalopin JM . C-reactive protein and cardiovascular disease in peritoneal dialysis patients . Kidney Int . 2002;62:1417–1422
  38. Yeun JY , Levine RA , Mantadilok V , Kaysen GA . C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients . Am J Kidney Dis . 2000;35:469–476
  39. Zimmermann J , Herrlinger S , Pruy A , Metzger T , Wanner C . Inflammation enhances cardiovascular risk and mortality in hemodialysis patients . Kidney Int . 1999;55:648–658
  40. Kato A , Takita T , Maruyama Y , Hishida A . Chlamydial infection and progression of carotid atherosclerosis in patients on regular haemodialysis . Nephrol Dial Transplant . 2004;19:2539–2546
  41. Stenvinkel P , Lindholm B , Heimburger M , Heimburger O . Elevated serum levels of soluble adhesion molecules predict death in predialysis patients: association with malnutrition, inflammation, and cardiovascular disease . Nephrol Dial Transplant . 2000;15:1624–1630
  42. Wang AY , Lam CW , Wang M , Woo J , Chan IH , Lui SF , et al.   Circulating soluble vascular cell adhesion molecule 1: relationships with residual renal function, cardiac hypertrophy, and outcome of peritoneal dialysis patients . Am J Kidney Dis . 2005;45:715–729
  43. Papagianni A , Kokolina E , Kalovoulos M , Vainas A , Dimitriadis C , Memmos D . Carotid atherosclerosis is associated with inflammation, malnutrition and intercellular adhesion molecule-1 in patients on continuous ambulatory peritoneal dialysis . Nephrol Dial Transplant . 2004;19:1258–1263
  44. Papagianni A, Kalovoulos M, Kirmizis D, Vainas A, Belechri AM, Alexopoulos E, et al. Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients . Nephrol Dial Transplant . 2003;18:113–119
  45. Rao M, Guo D, Perianayagam MC, Tighiouart H, Jaber BL, Pereira BJ, et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients . Am J Kidney Dis . 2005;45:324–333
  46. Panichi V , Maggiore U , Taccola D , Migliori M , Rizza GM , Consani C , et al.   Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients . Nephrol Dial Transplant . 2004;19:1154–1160
  47. Zoccali C , Mallamaci F , Tripepi G , Cutrupi S , Parlongo S , Malatino LS , et al.   Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure . J Intern Med . 2003;254:132–139
  48. Shlipak MG , Fried LF , Cushman M , Manolio TA , Peterson D , Stehman-Breen C , et al.   Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors . JAMA . 2005;293:1737–1745
  49. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy . Kidney Int . 1995;47:186–192
  50. Stewart GA , Gansevoort RT , Mark PB , Rooney E , McDonagh TA , Dargie HJ , et al.   Electrocardiographic abnormalities and uremic cardiomyopathy . Kidney Int . 2005;67:217–226
  51. van Hoeven KH , Factor SM . A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease . Circulation . 1990;82:848–855
  52. Wang AY , Sanderson J , Sea MM , Wang M , Lam CW , Li PK , et al.   Important factors other than dialysis adequacy associated with inadequate dietary protein and energy intakes in patients receiving maintenance peritoneal dialysis . Am J Clin Nutr . 2003;77:834–841
  53. Ates K , Nergizoglu G , Keven K , Sen A , Kutlay S , Erturk S , et al.   Effect of fluid and sodium removal on mortality in peritoneal dialysis patients . Kidney Int . 2001;60:767–776
  54. Bargman JM , Thorpe KE , Churchill DN . Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study . J Am Soc Nephrol . 2001;12:2158–2162
  55. Wang AY , Wang M , Woo J , Law MC , Chow KM , Li PK , et al.   A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients . Kidney Int . 2002;62:639–647
  56. Zoccali C , Mallamaci F , Maas R , Benedetto FA , Tripepi G , Malatino LS , et al.   Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients . Kidney Int . 2002;62:339–345
  57. Wang AY, Chan JC, Wang M, Poon E, Lui SF, Li PK, et al. Cardiac hypertrophy and remodeling in relation to ACE and angiotensinogen genes genotypes in Chinese dialysis patients . Kidney Int . 2003;63:1899–1907
  58. Schunkert H , Hense HW , Holmer SR , Stender M , Perz S , Keil U , et al.   Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy . N Engl J Med . 1994;330:1634–1638
  59. Osono E , Kurihara S , Hayama N , Sakurai Y , Ohwada K , Onoda N , et al.   Insertion/deletion polymorphism in intron 16 of the ACE gene and left ventricular hypertrophy in patients with end-stage renal disease . Am J Kidney Dis . 1998;32:725–730
  60. Zoccali C , Benedetto FA , Mallamaci F , Tripepi G , Giacone G , Cataliotti A , et al.   Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients . J Am Soc Nephrol . 2004;15:1029–1037
  61. Harnett JD , Foley RN , Kent GM , Barre PE , Murray D , Parfrey PS . Congestive heart failure in dialysis patients - prevalence, incidence, prognosis and risk factors . Kidney Int . 1995;47:884–890

PII: S1561-5413(09)60224-6

doi:10.1016/S1561-5413(09)60224-6

Hong Kong Journal of Nephrology
Volume 8, Issue 1 , Pages 10-16, April 2006

Article Tools